Lv64
1800 积分 2024-07-23 加入
The present and future of bispecific antibodies for cancer therapy
3天前
已完结
Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases
3天前
已完结
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis
5天前
已完结
CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis
5天前
已完结
The diagnostic performance of serum αvβ6 autoantibodies for ulcerative colitis: A systematic review and meta-analysis
14天前
已完结
Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Assessment
16天前
已完结
An FDA oncology analysis of immune activating products and first-in-human dose selection
16天前
已完结
Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a Bcell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
21天前
已完结
TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL
22天前
已完结
Bispecific T cell engager therapy for refractory rheumatoid arthritis
27天前
已完结
皖公网安备34019202002308
